1. Signaling Pathways
  2. Cell Cycle/DNA Damage
  3. CRISPR/Cas9

CRISPR/Cas9

The CRISPR/Cas9 system derived from bacterial adaptive immune systems is one of the most powerful genome editing technology. It is an RNA-guided genome editing tool that consists of a Cas9 nuclease and a single-guide RNA (sgRNA). By base-pairing with a DNA target sequence, the sgRNA enables Cas9 to recognize and cut a specific target DNA sequence, generating double strand breaks (DSBs) that trigger cell repair mechanisms and mutations at or near the DSBs sites. CRISPR/Cas9 technology has been studied extensively and its application has been expanded from the modification of the gene in cells to organisms. The potential role of CRISPR/Cas9 in gene therapy has made it to become one of the hottest pots in cancer treatment. Different concepts of CRISPR/Cas9-mediated cancer therapy, including tumor-related genes manipulating, tumor immunotherapy, tumor research modelling and anti-cancer drug resistance overcoming are established in various cancer types.

The greatest advantages of the CRISPR-Cas9 system are its simplicity and wide applicability in genome manipulations of almost all biological systems tested to date, including cell lines, stem cells, yeasts, worms, insects, rodents, and mammals. For a targetable DNA site, only a corresponding 20 nucleotide gRNA is needed to guide the CRISPR-Cas9 to cut the target DNA at the desired location. The repair of the broken DNA ends occurs either through NHEJ to generate indels, which has been used to generate random genomic mutations or through HDR in the presence of donor oligonucleotides or DNA fragments containing homologous sequences flanking the DSB sites to generate precise site-directed nucleotide or large gene replacements, leading to generation of targeted gene mutations or corrections.

CRISPR/Cas9 Related Products (10):

Cat. No. Product Name Effect Purity
  • HY-16592
    Brefeldin A Activator
    Brefeldin A (BFA) is a lactone antibiotic and a specific inhibitor of protein trafficking. Brefeldin A blocks the transport of secreted and membrane proteins from endoplasmic reticulum to Golgi apparatus. Brefeldin A is also an autophagy and mitophagy inhibitor. Brefeldin A is a CRISPR/Cas9 activator. Brefeldin A inhibits HSV-1 and has anti-cancer activity.
  • HY-13520
    Nocodazole Activator 98.63%
    Nocodazole (Oncodazole) is a rapidly-reversible inhibitor of microtubule. Nocodazole binds to β-tubulin and disrupts microtubule assembly/disassembly dynamics, which prevents mitosis and induces apoptosis in tumor cells. Nocodazole inhibits Bcr-Abl, and activates CRISPR/Cas9.
  • HY-11006
    KU-57788 Activator 99.35%
    KU-57788 (NU7441) is a highly potent and selective DNA-PK inhibitor with an IC50 of 14 nM. KU-57788 is an NHEJ pathway inhibitor. KU-57788 also inhibits PI3K and mTOR with IC50s of 5.0 and 1.7 μM, respectively.
  • HY-17413
    Zidovudine Agonist 99.82%
    Zidovudine is a nucleoside reverse transcriptase inhibitor (NRTI), widely used to treat HIV infection. Zidovudine increases CRISPR/Cas9-mediated editing frequency.
  • HY-107845
    SCR7 pyrazine Agonist 98.70%
    SCR7 pyrazine is a DNA ligase IV inhibitor that blocks nonhomologous end-joining (NHEJ) in a ligase IV-dependent manner. SCR7 pyrazine is also a CRISPR/Cas9 enhancer which increases the efficiency of Cas9-mediated homology-directed repair (HDR). SCR7 pyrazine induces cell apoptosis and has anticancer activity.
  • HY-19793
    RS-1 Activator 99.55%
    RS-1 is a RAD51 activator, and also increases CRISPR/Cas9-mediated knock-in efficiencies.
  • HY-12742
    SCR7 Agonist 98.22%
    SCR7 is an unstable form that can be autocyclized into a stable form SCR7 pyrazine. SCR7 pyrazine is a DNA ligase IV inhibitor that blocks nonhomologous end-joining (NHEJ) in a ligase IV-dependent manner. SCR7 pyrazine is also a CRISPR/Cas9 enhancer which increases the efficiency of Cas9-mediated homology-directed repair (HDR). SCR7 pyrazine induces cell apoptosis and has anticancer activity.
  • HY-19334
    L755507 Agonist ≥98.0%
    L755507 is a potent, selective agonist of β3-AR with an IC50 of 35 nM.
  • HY-136572
    CEM114
    CEM114 is an effective chemical epigenetic modifier (CEM) that recruits endogenous chromatin machinery through CRISPR-Cas9 systems.
  • HY-136251
    BRD0539 Inhibitor
    BRD0539 is a cell-permeable and non-toxic inhibitor of CRISPR-Cas9. BRD0539 inhibits Streptococcus pyogenes Cas9 (SpCas9) (apparent IC50=22 μM) in an in vitro DNA cleavage assay.
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.